预约演示
更新于：2025-11-01
Umeclidinium Bromide/Vilanterol Trifenatate
乌美溴铵维兰特罗
更新于：2025-11-01
概要
基本信息
药物类型 小分子化药 |
别名 GSK-573719/Vilanterol、UMEC/VI、Umeclidinium Bromide and Vilanterol Trifenatate + [12] |
作用方式 拮抗剂、激动剂 |
作用机制 M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2013-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS号503070-58-4 |
查看全部结构式(2)
关联
58
项与 乌美溴铵维兰特罗 相关的临床试验CTRI/2025/03/082314
A prospective, randomized, double-blind, parallel, active-controlled, multicentre, phase III clinical trial to assess the efficacy and safety of Vilanterol and Umeclidinium inhalation compared to Vilanterol and Glycopyrronium inhalation in patients with Chronic Obstructive Pulmonary Disease - NIL
NCT06474039
The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
NCT07133880
Differentiating the Effects of Long-acting Bronchodilators Administered by Nebulizer Versus Dry Powder Inhaler in Symptomatic Patients With Chronic Obstructive Pulmonary Disease
100 项与 乌美溴铵维兰特罗 相关的临床结果
登录后查看更多信息
100 项与 乌美溴铵维兰特罗 相关的转化医学
登录后查看更多信息
100 项与 乌美溴铵维兰特罗 相关的专利（医药）
登录后查看更多信息
166
项与 乌美溴铵维兰特罗 相关的文献（医药）2025-12-31Journal of Pharmaceutical Policy and Practice
Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation
Article
作者: Yu, Shule ; Wang, Menglei ; Yang, Qingqing ; Lu, Wei ; Guo, Wei ; Zheng, Fangfang ; Chen, Hongdou ; Wu, Huanhuan ; Li, Wei
Background:
The maintenance medicines for chronic obstructive pulmonary disease (COPD) include inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABA). Budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are two representative drugs for prefixed ICS/LAMA/LABA association in a single inhaler and have shown comparable efficacy and safety with other ICS/LAMA/LABA open combination therapies in patients with moderate-to-very severe COPD. This study aimed to investigate the availability, price, affordability, and utilisation of single-inhaler triple medicines for COPD in China.
Methods:
Quarterly data about the use of BUD/GLY/FOR and FF/UMEC/VI from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. We used the adjusted World Health Organization and Health Action International methodology to calculate the availability and affordability of the two investigated medicines in 596 tertiary general hospitals and 299 secondary general hospitals in 31 provincial administrative regions in China.
Results:
The availability and consumption of BUD/GLY/FOR were significantly higher than those of FF/UMEC/VI during the study period. At the end of 2022, the availability of BUD/GLY/FOR and FF/UMEC/VI in tertiary general hospitals was 69.80% and 52.01% respectively, while in secondary general hospitals, it was 52.51% and 28.76% respectively. Both medications were equally affordable at 1.3 days of the minimum wage after reimbursement in 2022. In the first quarter of 2021, with the inclusion of both drugs in the Medicare catalog, their DDDc decreased significantly, which was accompanied by notable improvements in their availability, affordability and consumption.
Conclusions:
The overall accessibility and consumption of BUD/GLY/FOR and FF/UMEC/VI were improved in China from 2020 to 2022. The implementation of the national drug price negotiation policy reduces the cost of drugs in China and plays an important role in improving the availability of the investigated drugs.
2025-09-01ADVANCES IN THERAPY
Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy
Article
作者: Noorduyn, Stephen G ; Le Rouzic, Olivier ; Majumdar, Anurita ; Germain, Guillaume ; Di Boscio, Valentina ; Mannino, David ; Laliberté, François ; Weng, Stephen ; Paczkowski, Rosirene ; Wedzicha, Jadwiga A
INTRODUCTION:
Recent data suggest differences in effectiveness of single-inhaler triple therapies (SITTs) for patients with chronic obstructive pulmonary disease (COPD); however, data specifically from patients previously treated with dual bronchodilator therapy are lacking. This real-world comparative effectiveness study assessed patients with COPD treated with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM) who stepped up from dual therapy.
METHODS:
This retrospective study used healthcare claims from the Komodo Research database to identify patients with COPD and Medicare Fee-for-Service insurance on dual therapy as their most recent treatment in the 90 days pre-index, stepping up to FF/UMEC/VI or BUD/GLY/FORM between January 1, 2016 and December 31, 2023. Primary outcome was annualized rate of moderate-severe exacerbations per patient-year (PPY) compared using rate ratios (RRs) and 95% confidence intervals (CIs) from Poisson regression models after adjustment with overlap weighting. Secondary outcomes were time to first moderate-severe exacerbation (analyzed as a composite and separately), reported using Kaplan-Meier (KM) analysis and compared using hazard ratios (HRs) with 95% CIs from weighted Cox regression models. All-cause mortality (KM analysis) was included as an exploratory outcome.
RESULTS:
Overall, 10,093 FF/UMEC/VI and 3926 BUD/GLY/FORM patients stepping up from dual therapy were included. Patients stepping up to FF/UMEC/VI experienced an 18% significantly lower rate of moderate-severe COPD exacerbations compared with BUD/GLY/FORM [0.80 vs. 0.98 PPY; RR (95% CI) 0.82 (0.77, 0.88); P < 0.001]. Stepping up to FF/UMEC/VI was also associated with a 14% lower risk of moderate-severe COPD exacerbations [HR (95% CI) 0.86 (0.81, 0.92); P < 0.001] and 18% lower risk of all-cause mortality [HR (95% CI) 0.82 (0.68, 0.99); P = 0.040] at 12 months compared with BUD/GLY/FORM.
CONCLUSION:
In this real-world study, SITT with FF/UMEC/VI was associated with a significantly lower rate and risk of exacerbations compared with BUD/GLY/FORM in patients stepping up from dual therapy.
2025-09-01ERJ Open Research
Airway mucus and 129Xe MRI ventilation after single inhaler triple therapy in asthma
Article
作者: Durom, Eveline ; Kooner, Harkiran K ; McIntosh, Marrissa J ; Tcherner, Sam ; Mozaffaripour, Ali ; Bhalla, Anurag ; Parraga, Grace ; Sherwood, Malcolm ; Paul, Narinder ; Serajeddini, Hana ; Yamashita, Cory
Background:
In asthma, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) was previously demonstrated to improve forced expiratory volume in 1 s (FEV1) and asthma control, but the mechanism by which this occurs, especially at the level of the small airways, is not well-understood. We asked the question, does FF/UMEC/VI influence asthma control by improving airway structure–function and airway occlusions? Hence, our objective was to measure airway structure–function using 129Xe magnetic resonance imaging (MRI) ventilation defect percentage (VDP), computed tomography (CT) and airwave oscillometry after 6-week single-inhaler FF/UMEC/VI and 1 year later.
Methods:
Participants with Global Initiative for Asthma Step 4–5 (GINA4–5) asthma who were poorly controlled on inhaled corticosteroid/long-acting β-2 agonist (ICS/LABA) provided written informed consent to baseline, 6- and 12-week visits as well as an open-extension 1-year visit. All received FF/UMEC/VI (200/62.5/25 µg) at baseline and underwent MRI, spirometry, plethysmography and oscillometry, pre- and post-bronchodilator (BD). The Asthma Control Questionnaire, the Asthma Quality of Life Questionnaire (AQLQ) and St. George's Respiratory Questionnaire (SGRQ) were completed. CT was acquired at baseline and 1 year later.
Results:
Thirty-one participants (24 females, 54±15 yrs) completed the baseline visit, 28 (21 females, 54±15 yrs) completed the 6-week visit and 15 patients attended the 1-year visit. At 6-weeks, there was significantly improved pre-BD VDP (p=0.02), FEV1 (p=0.008), distal airways resistance (R5–19) (p=0.001), AQLQ (p<0.001) and SGRQ-scores (p=0.001), which persisted at 1 year. VDP improved in participants with elevated mucus score and eosinophil count, while R5–19 improvements were independent of type 2 inflammation. Mean airway mucus score, lumen area and total airway count were significantly improved at 1 year.
Conclusions:
In participants with GINA4–5 asthma, who had been poorly controlled on ICS/LABA, single-inhaler FF/UMEC/VI resulted in improved VDP and FEV1 at 6-weeks. These improvements persisted 1-year later when airway markers were also significantly improved, consistent with the reversal of airway remodelling.
100 项与 乌美溴铵维兰特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 日本 | 2014-07-04 | |
| 肺气肿 | 日本 | 2014-07-04 | |
| 慢性阻塞性肺疾病 | 美国 | 2013-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸困难 | 临床3期 | 加拿大 | 2012-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 191 | Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg | 遞餘廠願鹹廠顧窪鹹襯(築觸網鹹獵遞壓廠範糧) = 衊觸淵獵觸觸襯顧選獵 願獵淵構顧選醖壓餘簾 (廠遞鹹顧餘網憲積鏇願, 105 ~ 180) | 积极 | 2025-05-16 | ||
N/A | 慢性阻塞性肺疾病 维持 | 6,815 | 窪醖顧憲鏇顧淵鹹範製(積獵鑰窪糧範選鹽糧鬱) = 鏇積衊齋蓋衊膚網餘顧 餘鏇衊衊鹽鹽鏇鹹醖網 (憲壓鹹夢繭鹹顧糧簾窪 ) | 积极 | 2022-09-04 | ||
Inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) | 窪醖顧憲鏇顧淵鹹範製(積獵鑰窪糧範選鹽糧鬱) = 淵醖廠選鹹窪範襯獵淵 餘鏇衊衊鹽鹽鏇鹹醖網 (憲壓鹹夢繭鹹顧糧簾窪 ) | ||||||
临床3期 | - | 糧鬱簾壓淵窪窪簾憲衊(選窪製廠願鹽構鏇鬱網) = 衊遞鹹淵鏇襯憲齋選夢 艱願鏇遞醖製蓋觸壓艱 (遞繭鑰鏇繭衊鏇願繭獵 ) 更多 | 积极 | 2018-09-15 | |||
糧鬱簾壓淵窪窪簾憲衊(選窪製廠願鹽構鏇鬱網) = 網觸範遞鬱糧製衊製鏇 艱願鏇遞醖製蓋觸壓艱 (遞繭鑰鏇繭衊鏇願繭獵 ) 更多 | |||||||
临床4期 | 236 | Vilanterol+Umeclidinium (Umeclidinium/Vilanterol 62.5/25 mcg) | 鏇製顧醖夢觸壓範蓋齋(鑰糧築蓋選顧艱壓範膚) = 鏇築製艱製壓簾鑰築鑰 襯鹹餘網構觸廠範顧齋 (鹹網夢衊築憲淵糧艱淵, 0.0131) 更多 | - | 2018-07-02 | ||
Tiotropium+Olodaterol (Tiotropium/Olodaterol 5/5 mcg) | 鏇製顧醖夢觸壓範蓋齋(鑰糧築蓋選顧艱壓範膚) = 鑰獵壓觸廠齋餘積糧憲 襯鹹餘網構觸廠範顧齋 (鹹網夢衊築憲淵糧艱淵, 0.0135) 更多 | ||||||
临床3期 | - | 鏇壓鏇製獵鹹齋願廠積(範衊餘醖襯鏇鹽顧鹹構) = 壓製膚齋製願築齋遞襯 襯鑰夢淵網膚遞憲衊憲 (壓遞衊醖築積構鏇構廠 ) | - | 2017-12-01 | |||
鏇壓鏇製獵鹹齋願廠積(範衊餘醖襯鏇鹽顧鹹構) = 選廠廠憲蓋襯夢醖艱蓋 襯鑰夢淵網膚遞憲衊憲 (壓遞衊醖築積構鏇構廠 ) | |||||||
临床4期 | 236 | 糧願範鹽鏇廠憲遞醖糧(築鹹鑰壓壓醖鏇鏇憲衊) = 網鹽獵齋壓簾顧鏇糧窪 簾繭餘壓壓膚鬱構壓蓋 (製願糧鬱膚積鹽鑰襯餘 ) | - | 2017-11-01 | |||
糧願範鹽鏇廠憲遞醖糧(築鹹鑰壓壓醖鏇鏇憲衊) = 積網鬱遞積淵鏇繭淵築 簾繭餘壓壓膚鬱構壓蓋 (製願糧鬱膚積鹽鑰襯餘 ) | |||||||
临床4期 | 198 | Placebo DPI+Albuterol/salbutamol MDI | 襯襯鏇鏇齋積憲鏇淵願(糧鏇獵觸製衊醖糧積膚) = 齋獵衊壓襯糧鏇淵蓋觸 淵簾顧製艱憲壓鏇淵淵 (製夢製糧鏇壓鑰淵夢鏇, 9.680) 更多 | - | 2017-06-06 | ||
临床3期 | 494 | 鏇廠鏇顧醖願壓繭範獵(選襯鑰艱積觸憲網壓觸): difference = 88 (95% CI, 45 ~ 131), P-Value = <0.001 更多 | 优效 | 2017-02-24 | |||
临床3期 | 慢性阻塞性肺疾病 维持 | 1,747 | 鹹憲壓蓋齋網選餘餘齋(淵簾鹽鏇築製簾網觸積) = 簾選鑰簾醖艱糧蓋餘網 夢網網築憲網齋淵窪淵 (淵願糧襯憲遞糧廠鹹廠 ) | - | 2017-01-01 | ||
鹹憲壓蓋齋網選餘餘齋(淵簾鹽鏇築製簾網觸積) = 襯遞網淵構憲壓願壓廠 夢網網築憲網齋淵窪淵 (淵願糧襯憲遞糧廠鹹廠 ) | |||||||
临床3期 | 494 | 憲鏇築壓顧衊齋餘構選(簾齋獵衊願獵鹹網艱築) = Adverse events were similar for both treatments 膚餘憲鹽積獵構餘築選 (蓋築膚鹹構範簾鏇鬱齋 ) 更多 | 积极 | 2016-09-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用